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Newly published studies validate prior reports that specific combinations of genetic alternations in IDH1/2,
ATRX, TERT, TP53, and co-deletion of 1p/19q have the ability to reclassify gliomas into rational subsets,
defining a glioma’s biological and clinical behavior more accurately than stratifications based solely on
histopathology.Gliomas, which include astrocytomas,
oligodedrogliomas, oligoastrocytomas,
and glioblastomas (GBMs), are identified
and treated based on common histo-
pathological criteria. However, these
criteria may not accurately predict clinical
outcome because assessment methods
currently used in the clinic are overly
subjective, inconsistent, and possess
little power to distinguish the mixed
histological appearance of glioma tissue
(Olar and Sulman, 2015). Up to 43%
of neuro-oncology case reviews utilizing
histopathology for glial tumor identifi-
cation result in some degree of disagree-
ment, 9% of which have documented
serious clinical consequences resulting
from this uncertainty (Bruner et al., 1997).
Over the past decade, large-scale ge-
netic sequencing efforts have identified
key genomic alterations across glial
subtypes, including mutations in CIC,
FUBP1, 1p/19q co-deletion, IDH1/2,
TERT, ATRX, and the alternative length-
ening of telomeres (ALT) phenotype. The
FUBP1 and CIC mutations, recently iden-
tified in oliodendrogliomas, correspond
to chromosome 1p and 19q, respectively,and may represent key tumor suppres-
sors uncovered by loss of heterozygosity
(LOH) or co-deletion at 1p/19q (Bette-
gowda et al., 2011). Individually, each
somatic alteration has demonstrated
prognostic value in gliomas and other
tumor types (Jenkins et al., 2006; Parsons
et al., 2008; Bettegowda et al., 2011;
Killela et al., 2013).
In 2012, Jiao et al. were the first to
integrate these markers into a classifi-
cation model across adult gliomas (Jiao
et al., 2012). This initial model classified
gliomas by assessing the mutation sta-
tus of IDH, ATRX, and CIC/FUBP1,
correlating the genetic information
with histopathologic data and clinical
outcome, and ultimately partitioned gli-
omas into subgroups based on shared
genetic and clinical characteristics.
Three subgroups emerged from this
initial observation. Group 1 tumors
were characterized by mutations in
IDH1 and ATRX and mainly demon-
strated an astrocytoma phenotype
on histopathology. Group 2 tumors
harbored mutation in IDH1, CIC, and
FUBP1; the majority demonstrated oli-godendroglioma histology. Finally, group
3 tumors were wild-type for IDH and
ATRX and were consistent with grade
IV GBM histology. Patients with group
1 tumors demonstrated a median sur-
vival of 4.3 years, patients with group 2
tumors had a median survival of 8 years,
and patients suffering with gliomas of
the group 3 genotype had a median sur-
vival of 1.1 years.
In 2013, the discovery of promoter
mutations in TERT in large numbers of
gliomas led to a more refined classifica-
tion (Killela et al., 2013). TERT promoter
mutations were found in 83% of primary
glioblastomas and were mutually exclu-
sive with ATRX mutations and the ALT
phenotype, which was most evident
in astrocytomas (Killela et al., 2013).
Furthermore, the ALT phenotype and
ATRX mutations were found to be
strongly linked in virtually all cases,
suggesting a strong biologic correlation
between disruption of ATRX and ALT.
These data also provided supported
the notion that telomere maintenance
was an important feature of many gli-
omas and that two mutually exclusiveell 28, July 13, 2015 ª2015 Elsevier Inc. 9
Figure 1. Schematic Representation of Combined Findings from Jiao et al. (2012), Killela et al. (2013), Brat et al. (2015), and Eckel-Passow
et al. (2015).
Characteristic molecular signature groups are determined based on the tumor status of IDH and Iq/19p combined with cancer telomere maintenance
strategy (TERT or ATRX mutation conferring telomerase or ALT telomere maintenance, respectively). Each subgroup is associated with the predominate
histology most frequently witnessed with the respective genetic signature as well as relative survival. Acronyms in the schematic include IDH (isocitrate
dehydrogenase), TERT (telomerase reverse transcriptase), and ATRX (alpha-thalassemia/mental retardation syndrome X-linked) as well as the subgroups
‘‘IT’’ (IDH and TERT) and ‘‘IA’’ (IDH and ATRX). Triple-positive tumors refer to gliomas with IDH and TERT mutations and with co-deletion of 1q/19p.
Triple-negative tumors refer to gliomas wild-type for IDH, TERT and without with co-deletion of 1q/19p. Frequency estimates are derived from Eckel-
Passow et al. (2015).
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Previewspathways (TERT versus ATRX/ALT) exist
in these tumors (Killela et al., 2013).
In the past month, two independent
studies published in the New England
Journal of Medicine (NEJM) have re-
ported on the clinical value of 1p/19q
co-deletions, IDH, TERT, TP53, and
ATRX mutations in gliomas (Brat et al.,
2015; Eckel-Passow et al., 2015). The
study by Brat et al. (2015) of the Cancer
Genome Atlas Research Network as-
sessed the genomic and epigenomic
landscapes of low and intermediate
grade II and III gliomas using integrated
analyses of gene and microRNA expres-
sion, genomic analysis, and DNA methyl-
ation. This multi-platform approach
yielded three groups similar to those
initially described by Jiao’s model. One
set of tumors was classified by IDHmuta-
tion and 1p/19q co-deletion; a second
set included tumors with IDH mutation
only; and a third set of tumors possessed
wild-type IDH and no co-deletion in
1p/19q. Tumors sharing each molecular
signature demonstrated much higher in-
ternal concordance compared to tumor
groups formed from solely histopatholog-
ical assignment. Gliomas with IDH muta-10 Cancer Cell 28, July 13, 2015 ª2015 Elsevtions and co-deletion in 1p/19q alone
demonstrated the longest overall median
survival of 8.0 years, and those with IDH
mutation only without 1p/19q co-deletion
had a median survival of 6.3 years. Those
patients with tumors with wild-type IDH
had a median survival of 1.7 years, and
these IDH wild-type tumors had a similar
profile to GBM.
A second NEJM study in the same issue
reported on the use ofTERTpromoter, IDH
1/2mutations, and 1p/19q co-deletions to
classify gliomas (Eckel-Passow et al.,
2015). The investigators observed that
almost all stage II–IV gliomas evaluated
were successfully matched into one of
fivemolecular subgroups defined by these
markers: group 1 were triple mutant tu-
mors with mutations in IDH, TERT and
with 1p/19q co-deletion; group 2 were tu-
mors with both IDH and TERT mutations;
group 3 were tumors with IDH mutations
alone, without TERTmutations and absent
1p/19q co-deletion; group 4 were triple-
negative tumors without mutations in IDH,
TERT, or 1p/19q co-deletion; and group 5
were tumors with TERT mutations alone,
without IDH mutations and absent 1p/19q
co-deletion. Tumors with TERT mutationsier Inc.alone (group 5) and those triple-negative
tumors (group 4) carried the highest risk
for patient mortality compared to patients
with tumors with IDH mutations in any
combination of TERT mutation or 1p/19q
co-deletion (groups 1–3), further affirming
the pacifying effects of IDH mutations on
prognosis.
How these classification models will
be used in the clinic remains unknown,
especially since acceptance of molecu-
lar tests by physicians who treat gliomas
has been mixed (Holdhoff et al., 2012).
Whether these genetic signatures will
be used after histopathologic diagnosis
or upfront for all cases at diagnosis will
depend on the value derived from the
eventual application of these markers
to real-life clinical scenarios. One advan-
tage of these studies is the high degree
of consistency between prior studies
and the more recent reports, which
show that a molecular classification of
gliomas using ATRX (ALT), IDH1/2,
TERT, and 1p/19q status may the best
indicators of tumor behavior and prog-
nosis and, in the future, could inform
therapeutic decisions (Figure 1). The
data strongly suggest that tumors of
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Previewscomplex origin may visually appear
similar but have very different underlying
mutational profiles. Integrating histology
with genetic alterations for tumor classi-
fication may be essential to classifying
heterogeneous tumors such as oligoas-
trocytomas, which demonstrate mixed
histologic features and no defining ge-
netic signature. Barriers still exist before
this can become routine clinical practice,
including the cost and complexity of
genetic analysis and the lack of pro-
spective trials validating these genetic
signatures for clinical prognosis. Ulti-
mately, advances in sequencing tech-
nology will enable these biomarkers
to be incorporated into inexpensive and
routine tests.REFERENCES
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Immune checkpoint-blocking therapies have yielded positive clinical data in a series of humanmalignancies.
Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-defi-
cient tumors, independent of underlying tumor type. These data suggest the importance of sensing the
consequences of DNA damage in cancer immunotherapy.Over the past few years, therapies that
interfere with T cell checkpoints and, in
particular, the PD-1/PD-L1 axis, have
reached center stage in oncology. Clinical
trials with anti-PD-1 and anti-PD-L1
antibodies have now shown objective
responses in a series of human malig-
nancies, including non-small cell lung
cancer (NSCLC), bladder cancer, renal
cell carcinoma, and Hodgkin’s lymphoma
(Topalian et al., 2012). In non-melanoma
tumors, clinical development of anti-
PD-1 therapy is most advanced for
NSCLC, with recent approval by FDA as
second-line therapy.
A proposed explanation for the activity
of T cell checkpoint blockade in tumors
such as melanoma and NSCLC hasbeen the boosting of T cell reactivity
against ‘‘neo-antigens’’, T cell epitopes
that are newly formed as a consequence
of tumor-specific mutations (Schumacher
and Schreiber, 2015). In line with this,
T cell checkpoint blockade has been
shown to enhance neo-antigen-specific
T cell responses in both diseases (Rizvi
et al., 2015; van Rooij et al., 2013).
Contrary to the data in a number of
other tumor types, clinical testing of
anti-PD-1 has thus far not shown encour-
aging results in colorectal cancer (CRC).
In two trials, a total of 33 CRC patients
were treated with anti-PD-1 therapy and
only 1 patient (3%) experienced an
objective response, which was, however,
a complete response (Topalian et al.,2012). Interestingly, the tumor of this pa-
tient displayed a hyper-mutated pheno-
type, a characteristic of approximately
4% of metastasized colorectal cancers.
Basedon thesedata, Le andcolleagues
hypothesized that patients with mismatch
repair-defects might be particularly
responsive to checkpoint targeting. They
now provide compelling data in favor of
this hypothesis in a recent publication in
the New England Journal of Medicine
(Le et al., 2015). In a phase II study that
evaluated the activity of PD-1 blockade
in 41 patients, 3 cohorts of patients were
included: 11 patients with mismatch
repair-deficient CRC, 21 patients with
mismatch repair-proficient CRC, and 9
patients with mismatch repair-deficientell 28, July 13, 2015 ª2015 Elsevier Inc. 11
